Caris Life Sciences, Inc.
CAI
$27.24
$1.134.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | 133.88% | 30.02% | -2.33% | ||
| Total Depreciation and Amortization | -24.01% | -9.03% | -9.29% | ||
| Total Amortization of Deferred Charges | -68.24% | 298.71% | 5.43% | ||
| Total Other Non-Cash Items | -74.86% | 35.60% | 145.97% | ||
| Change in Net Operating Assets | 1,078.94% | -110.80% | -308.02% | ||
| Cash from Operations | 756.55% | 123.26% | -10.33% | ||
| Capital Expenditure | -411.90% | 48.46% | 29.37% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -411.90% | 48.46% | 29.37% | ||
| Total Debt Issued | -100.00% | -- | -- | ||
| Total Debt Repaid | -4.55% | 0.00% | 13.33% | ||
| Issuance of Common Stock | -99.78% | 36,835.08% | 66.67% | ||
| Repurchase of Common Stock | -898.79% | -7,436.36% | -- | ||
| Issuance of Preferred Stock | -100.00% | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -230.83% | 4,223.81% | -10.16% | ||
| Cash from Financing | -103.10% | 52,927.39% | 167.44% | ||
| Foreign Exchange rate Adjustments | -33.33% | 2,225.00% | -233.33% | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -95.01% | 2,199.69% | -8.46% | ||